AI Summary
Thinking
Thinking
We reviewed 215 live results for actemra intravenous iv infusion and narrowed them down to the 3 options that look most worth comparing first.
The options are Actemra Intravenous (IV) Infusion, Actemra Subcutaneous (SC) Injection, and Truxima Intravenous Infusion Administration.
Source: Roche
Description
Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage.
Best for
Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital Based IV treatment and Thai local access
Rate this product
Source: Roche
Description
A ready-to-use subcutaneous injection of tocilizumab available as a 162 mg / 0.9 mL solution in a single-use pre-filled syringe (PFS). This formulation allows for self-administration by patients with rheumatoid arthritis or juvenile idiopathic arthritis, providing a more flexible alternative to clinical infusion sessions. It is registered with the Thai FDA and offers a convenient delivery method for long-term chronic disease management.
Best for
Self Administration at home, Chronic RA maintenance, Patient convenience and Thailand registered biologics
Rate this product
Source: Hospital Kuala Lumpur
Description
Clinical administration of Truxima (rituximab biosimilar) for the treatment of hematological cancers and autoimmune disorders, provided within a supervised hospital setting with specialized oncology support.
Best for
Public healthcare patients, Hematological malignancy treatment, Supervised IV infusion and Oncology care in Kuala Lumpur
Rate this product
| Compare | #1Actemra Intravenous (IV) Infusion | #2Actemra Subcutaneous (SC) Injection | #3Truxima Intravenous Infusion Administration |
|---|---|---|---|
| Source | Roche | Roche | Hospital Kuala Lumpur |
| Description | Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage. | A ready-to-use subcutaneous injection of tocilizumab available as a 162 mg / 0.9 mL solution in a single-use pre-filled syringe (PFS). This formulation allows for self-administration by patients with rheumatoid arthritis or juvenile idiopathic arthritis, providing a more flexible alternative to clinical infusion sessions. It is registered with the Thai FDA and offers a convenient delivery method for long-term chronic disease management. | Clinical administration of Truxima (rituximab biosimilar) for the treatment of hematological cancers and autoimmune disorders, provided within a supervised hospital setting with specialized oncology support. |
| Best for | Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital Based IV treatment and Thai local access | Self Administration at home, Chronic RA maintenance, Patient convenience and Thailand registered biologics | Public healthcare patients, Hematological malignancy treatment, Supervised IV infusion and Oncology care in Kuala Lumpur |
| Action | Actemra Intravenous (IV) Infusion | Actemra Subcutaneous (SC) Injection | Truxima Intravenous Infusion Administration |
| Rate this product |
"Actemra Intravenous (IV) Infusion from Roche."
TopFind picked this because This is the primary originator brand registered and commercially available in Thailand, with established government reference pricing and local distribution.
Note: TopFind provides comparison information for general research purposes only.